ACUT
AccuStem Sciences, Inc.
Price Chart
Latest Quote
$0.60
Current Price| Previous Close | $0.58 |
| Open | $0.60 |
| Day High | $0.60 |
| Day Low | $0.60 |
| Volume | 1,000 |
Stock Information
| Shares Outstanding | 16.07M |
| Total Debt | $45K |
| Cash Equivalents | $14K |
| Net Income | $-1.61M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $9.64M |
| EPS (TTM) | $-0.11 |
| Exchange | OQB |
đ Custom Metrics & Score
Score: 13/42| Debt to Equity | -0.01 |
| Debt to Earnings | -0.02 |
| Current Ratio | 0.01 |
| Quick Ratio | 0.00 |
| Return on Equity | 45.43% |
| Avg FCF Growth | -21.15% |
| FCF Yield | -6.89% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $0.58 | 100 |
| 2026-01-30 | $0.60 | 0 |
| 2026-01-29 | $0.60 | 3,102 |
| 2026-01-28 | $0.58 | 0 |
| 2026-01-27 | $0.58 | 7,498 |
| 2026-01-26 | $0.60 | 173 |
| 2026-01-23 | $0.63 | 1,277 |
| 2026-01-22 | $0.65 | 1,130 |
| 2026-01-21 | $0.64 | 322 |
| 2026-01-20 | $0.62 | 1,183 |
| 2026-01-16 | $0.60 | 6,219 |
| 2026-01-15 | $0.70 | 0 |
| 2026-01-14 | $0.70 | 920 |
| 2026-01-13 | $0.85 | 0 |
| 2026-01-12 | $0.85 | 202 |
| 2026-01-09 | $0.76 | 4,363 |
| 2026-01-08 | $0.70 | 531 |
| 2026-01-07 | $0.60 | 1,102 |
| 2026-01-06 | $0.81 | 0 |
| 2026-01-05 | $0.81 | 0 |
About AccuStem Sciences, Inc.
AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. It offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. The company also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. The company has a partnership with EmeritusDX for the development of non-invasive blood testing technologies. AccuStem Sciences, Inc. was founded in 2013 and is headquartered in New York, New York.
đ° Latest News
No news articles available at the moment. Check back later for updates on ACUT.
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Revenue | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Expenses | $1,505,102 | $2,050,664 | $3,746,419 |
| Operating Expense | $1,505,102 | $2,050,664 | $3,746,419 |
| General And Administrative Expense | $1,366,778 | $1,911,001 | $3,479,486 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Normalized Income | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Net Income From Continuing And Discontinued Operation | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Total Operating Income As Reported | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Net Income Common Stockholders | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Net Income | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Net Income Including Noncontrolling Interests | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Net Income Continuous Operations | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Pretax Income | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Operating Income | $-1,505,102 | $-2,050,664 | $-3,746,419 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Diluted EPS | $-0.13 | $-0.18 | $-0.34 |
| Basic EPS | $-0.13 | $-0.18 | $-0.34 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-1,501,472 | $-2,047,034 | $-3,743,098 |
| Reconciled Depreciation | $3,630 | $3,630 | $3,321 |
| EBITDA (Bullshit earnings) | $-1,501,472 | $-2,047,034 | $-3,743,098 |
| EBIT | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Diluted Average Shares | $11,435,362 | $11,346,535 | $11,016,165 |
| Basic Average Shares | $11,435,362 | $11,346,535 | $11,016,165 |
| Diluted NI Availto Com Stockholders | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Tax Provision | $0 | $0 | $0 |
| Research And Development | $138,324 | $139,663 | $266,933 |
| Selling General And Administration | $1,366,778 | $1,911,001 | $3,479,486 |
| Other Gand A | $1,366,778 | $1,911,001 | $3,479,486 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Net Tangible Assets | $-3,313,224 | $-2,111,580 | $-139,550 |
| Total Assets | $50,851 | $133,897 | $939,689 |
| Total Non Current Assets | $418 | $4,048 | $7,678 |
| Current Assets | $50,433 | $129,849 | $932,011 |
| Prepaid Assets | $45,387 | $108,368 | $168,430 |
| Cash Cash Equivalents And Short Term Investments | $5,046 | $21,481 | $733,978 |
| Cash And Cash Equivalents | $5,046 | $21,481 | $733,978 |
| Cash Financial | $5,046 | $21,481 | $733,978 |
| Other Current Assets | - | - | $29,603 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Net Debt | $20,102 | $34,198 | - |
| Total Debt | $25,148 | $55,679 | $106,551 |
| Current Debt And Capital Lease Obligation | $25,148 | $55,679 | $106,551 |
| Current Debt | $25,148 | $55,679 | $106,551 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Liabilities Net Minority Interest | $3,364,075 | $2,245,477 | $1,079,239 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 |
| Current Liabilities | $3,364,075 | $2,245,477 | $1,079,239 |
| Current Notes Payable | $25,148 | $55,679 | $106,551 |
| Payables And Accrued Expenses | $3,338,927 | $2,189,798 | $972,688 |
| Payables | $3,174,874 | $2,033,364 | $454,063 |
| Accounts Payable | $804,615 | $578,378 | $311,834 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Common Stock Equity | $-3,313,224 | $-2,111,580 | $-139,550 |
| Total Equity Gross Minority Interest | $-3,313,224 | $-2,111,580 | $-139,550 |
| Stockholders Equity | $-3,313,224 | $-2,111,580 | $-139,550 |
| Retained Earnings | $-8,027,047 | $-6,521,945 | $-4,471,281 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Ordinary Shares Number | $12,100,535 | $11,346,535 | $11,346,535 |
| Share Issued | $12,100,535 | $11,346,535 | $11,346,535 |
| Tangible Book Value | $-3,313,224 | $-2,111,580 | $-139,550 |
| Invested Capital | $-3,288,076 | $-2,055,901 | $-32,999 |
| Working Capital | $-3,313,642 | $-2,115,628 | $-147,228 |
| Total Capitalization | $-3,313,224 | $-2,111,580 | $-139,550 |
| Additional Paid In Capital | $4,701,723 | $4,399,019 | $4,320,385 |
| Capital Stock | $12,100 | $11,346 | $11,346 |
| Common Stock | $12,100 | $11,346 | $11,346 |
| Preferred Stock | $0 | $0 | $0 |
| Current Accrued Expenses | $164,053 | $156,434 | $518,625 |
| Dueto Related Parties Current | $2,370,259 | $1,454,986 | $142,229 |
| Net PPE | $418 | $4,048 | $7,678 |
| Accumulated Depreciation | $-10,581 | $-6,951 | $-3,321 |
| Gross PPE | $10,999 | $10,999 | $10,999 |
| Machinery Furniture Equipment | $10,999 | $10,999 | $10,999 |
| Treasury Shares Number | - | $0 | - |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Free Cash Flow | $-664,066 | $-1,615,643 | $-1,817,052 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Operating Cash Flow | $-664,066 | $-1,615,643 | $-1,806,053 |
| Cash Flow From Continuing Operating Activities | $-664,066 | $-1,615,643 | $-1,806,053 |
| Operating Gains Losses | - | - | $-66,981 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Investing Cash Flow | $0 | $0 | $-10,999 |
| Cash Flow From Continuing Investing Activities | $0 | $0 | $-10,999 |
| Capital Expenditure | - | - | $-10,999 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Issuance Of Capital Stock | $0 | $0 | $2,675,940 |
| Financing Cash Flow | $647,632 | $903,146 | $2,551,030 |
| Cash Flow From Continuing Financing Activities | $647,632 | $903,146 | $2,551,030 |
| Net Other Financing Charges | $781,077 | $1,246,757 | $204,879 |
| Net Common Stock Issuance | $0 | $0 | $2,675,940 |
| Common Stock Issuance | $0 | $0 | $2,675,940 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Repayment Of Debt | $-133,445 | $-343,611 | $-338,258 |
| Interest Paid Supplemental Data | $3,392 | $7,192 | $7,474 |
| End Cash Position | $5,047 | $21,481 | $733,978 |
| Beginning Cash Position | $21,481 | $733,978 | $0 |
| Changes In Cash | $-16,434 | $-712,497 | $733,978 |
| Proceeds From Stock Option Exercised | $0 | $0 | $8,469 |
| Net Issuance Payments Of Debt | $-133,445 | $-343,611 | $-338,258 |
| Net Short Term Debt Issuance | $-133,445 | $-343,611 | $-338,258 |
| Short Term Debt Payments | $-133,445 | $-343,611 | $-338,258 |
| Net PPE Purchase And Sale | $0 | $0 | $-10,999 |
| Purchase Of PPE | $0 | $0 | $-10,999 |
| Change In Working Capital | $533,948 | $352,757 | $1,870,137 |
| Change In Other Current Assets | $0 | $29,603 | $-29,603 |
| Change In Payables And Accrued Expense | $368,053 | $-19,968 | $275,675 |
| Change In Accrued Expense | $7,620 | $-352,512 | $401,130 |
| Change In Payable | $360,433 | $332,544 | $-125,455 |
| Change In Account Payable | $226,237 | $266,544 | $-76,846 |
| Change In Prepaid Assets | $165,895 | $343,122 | $270,692 |
| Change In Receivables | $0 | $0 | $1,353,373 |
| Stock Based Compensation | $303,458 | $78,634 | $133,889 |
| Depreciation Amortization Depletion | $3,630 | $3,630 | $3,321 |
| Depreciation And Amortization | $3,630 | $3,630 | $3,321 |
| Depreciation | $3,630 | $3,630 | $3,321 |
| Net Income From Continuing Operations | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Net Foreign Currency Exchange Gain Loss | - | $0 | $-66,981 |